文献速递眼底病与葡萄膜炎

新生物标志物量化抗血管内皮生长因子治疗对增生型糖尿病视网膜病变患眼超广角荧光素血管造影的影响:RECOVERY研究

NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study.
PubMed 文献 · Retina · 2022-01-01

本研究为前瞻性观察性研究,纳入40只伴显著无灌注的增生型糖尿病视网膜病变患眼,于基线和6个月时行超广角荧光素血管造影,经立体投影校正后自动计算视网膜血管床面积(RVBA)。抗血管内皮生长因子治疗后,全 cohort 整体RVBA从67.1±15.5 mm²降至43.6±18.8 mm²(P<0.001),每月注射亚组从68.7±16.2降至33.9±13.3 mm²(P<0.001),每三月注射亚组从65.6±15.1降至50.8±19.3 mm²(P=0.004)。作者认为RVBA似乎可作为反映抗血管内皮生长因子治疗后视网膜血管变化的生物标志物。

要点

  • 伴显著无灌注的增生型糖尿病视网膜病变患眼抗血管内皮生长因子治疗后6个月整体RVBA从67.1±15.5降至43.6±18.8 mm²(P<0.001)。
  • 每月注射亚组RVBA从68.7±16.2降至33.9±13.3 mm²(P<0.001),每三月注射亚组从65.6±15.1降至50.8±19.3 mm²(P=0.004)。
  • 作者认为RVBA似乎可作为指示抗血管内皮生长因子注射后视网膜血管变化效率的新生物标志物。

核心结论

  • RVBA似乎可作为指示抗血管内皮生长因子注射后视网膜血管变化效率的新生物标志物。
  • 伴显著无灌注的增生型糖尿病视网膜病变患眼在抗血管内皮生长因子治疗后显示RVBA减小。

研究设计与样本

  • 前瞻性观察性研究,纳入40只伴显著无灌注的增生型糖尿病视网膜病变患眼(NCT02863354)。
  • 于基线和6个月时获取早期超广角荧光素血管造影图像(Optos 200Tx),经立体投影校正周边畸变后自动提取视网膜血管并求和像素真实面积(mm²)计算RVBA。

主要发现

  • 整个队列全视网膜整体RVBA在抗血管内皮生长因子治疗6个月后从67.1±15.5降至43.6±18.8 mm²(P<0.001)。
  • 每月接受抗血管内皮生长因子注射的亚组整体RVBA从68.7±16.2降至33.9±13.3 mm²(P<0.001)。
  • 每三个月接受抗血管内皮生长因子注射的亚组整体RVBA从65.6±15.1降至50.8±19.3 mm²(P=0.004)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection. METHODS: This is a prospective, observational study. The early-phase ultrawide field fluorescein angiography images (Optos 200Tx) of 40 eyes with proliferative diabetic retinopathy and significant nonperfusion obtained at baseline and after six months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on ultrawide field fluorescein angiography was extracted for calculating RVBA by summing the real size (mm2) of all the pixels automatically. RESULTS: For the entire cohort, the global RVBA for the entire retina decreased from 67.1 ± 15.5 to 43.6 ± 18.8 mm2 after anti-VEGF treatment at six months (P < 0.001). In the subgroup receiving monthly anti-VEGF injections, the global RVBA decreased from 68.7 ± 16.2 to 33.9 ± 13.3 mm2 (P < 0.001). In the subgroup receiving anti-VEGF every three months, the global RVBA decreased from 65.6 ± 15.1 to 50.8 ± 19.3 mm2 (P = 0.004). CONCLUSION: RVBA seems to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with proliferative diabetic retinopathy and significant nonperfusion demonstrate reduced RVBA after anti-VEGF treatment.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Fan W, Nittala MG, Wykoff CC, et al. NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study. Retina. 2022. PMID: 34803132. doi:10.1097/IAE.0000000000003358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。